Meta-Analysis: Diagnostic Accuracy of Antinuclear Antibodies, Smooth Muscle Antibodies and Antibodies to a Soluble Liver Antigen/Liver Pancreas in Autoimmune Hepatitis

被引:35
作者
Zhang, Wen-Chao [1 ]
Zhao, Feng-Rong [2 ]
Chen, Juan [3 ]
Chen, Wei-Xian [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 2, Dept Lab Med, Chongqing, Peoples R China
[2] Youyang Peoples Hosp, Dept Obstet & Gynaecol, Chongqing, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Chongqing, Peoples R China
基金
中国国家自然科学基金;
关键词
PRIMARY BILIARY-CIRRHOSIS; CHRONIC ACTIVE HEPATITIS; OVERLAP SYNDROME; F-ACTIN; SCLEROSING CHOLANGITIS; INITIAL PRESENTATION; ANTIACTIN ANTIBODY; MEDICAL PROGRESS; RISK-FACTORS; AUTOANTIBODIES;
D O I
10.1371/journal.pone.0092267
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Antinuclear antibodies (ANA), smooth muscle antibodies (SMA) and antibodies to a soluble liver antigen/liver pancreas (anti-SLA/LP) are useful markers that can help clinicians to diagnose and classify autoimmune hepatitis (AIH). Objectives: To determine whether ANA, SMA and anti-SLA/LP help to accurately diagnose patients with AIH. Search strategy: The PubMed, CNKI, WANFANG, and SinoMed databases were accessed to retrieve studies published in English and Chinese. Studies published up to October 2013 were reviewed. Selection criteria: Studies on the diagnostic value of ANA, SMA or anti-SLA/LP in the diagnosis of known or suspected AIH were included. Data collection and analysis: Two authors evaluated studies independently and rated their methodological quality using quality assessment of diagnostic accuracy studies (QUADAS) tools; relevant data were abstracted. The random-effects method was used to summarize sensitivities, specificities, positive and negative likelihood ratios, and diagnostic odds ratios (DORs) from all 29 studies. Results: The pooled sensitivity, specificity, positive and negative likelihood ratios, and DOR for ANA were 0.650 (95% confidence interval [CI], 0.619 to 0.680), 0.751 (95% CI, 0.737 to 0.764), 3.030 (95% CI, 2.349 to 3.910), 0.464 (95% CI, 0.356 to 0.604), and 7.380 (95% CI, 4.344 to 12.539), respectively. For SMA, the values were 0.593 (95% CI, 0.564 to 0.621), 0.926 (95% CI, 0.917 to 0.934), 11.740 (95% CI, 7.379 to 18.678), 0.449 (95% CI, 0.367 to 0.549), and 31.553 (95% CI, 17.147 to 58.060), respectively. Finally, for anti-SLA/LP, the values were 0.194 (95% CI, 0.168 to 0.222), 0.989 (95% CI, 0.985 to 0.993), 11.089 (95% CI, 7.601 to 16.177), 0.839 (95% CI, 0.777 to 0.905), and 16.867 (95% CI, 10.956 to 25.967), respectively. Authors' conclusions: ANA provided moderate sensitivity and specificity, while SMA gave moderate sensitivity and high specificity, and anti-SLA/LP exhibited low sensitivity and high specificity. All three antibodies were limited by their unsatisfactory sensitivities and lack of consistency.
引用
收藏
页数:13
相关论文
共 114 条
[91]  
STECHEMESSER E, 1993, HEPATOLOGY, V18, P1
[92]   A likelihood ratio approach to meta-analysis of diagnostic studies [J].
Stengel, D ;
Bauwens, K ;
Sehouli, J ;
Ekkernkamp, A ;
Porzsolt, F .
JOURNAL OF MEDICAL SCREENING, 2003, 10 (01) :47-51
[93]   Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases [J].
Strassburg, CP ;
Alex, B ;
Zindy, F ;
Gerken, G ;
Luttig, B ;
zumBuschenfelde, KHM ;
Brechot, C ;
Manns, MP .
JOURNAL OF HEPATOLOGY, 1996, 25 (06) :859-866
[94]  
Tan Li-ming, 2006, Zhonghua Gan Zang Bing Za Zhi, V14, P463
[95]  
[谭立明 TAN Liming], 2009, [免疫学杂志, Immunological Journal], V25, P697
[96]  
Tan LiMing Tan LiMing, 2013, Chinese Journal of Immunology, V29, P839
[97]  
Tan LM, 2012, CHIN J IMMUNOL, V12, P1061
[98]  
Tan LM, 2006, WORLD J GASTROENTERO, V14, P2801
[99]  
URIBE M, 1984, J CLIN GASTROENTEROL, V6, P331
[100]   High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis [J].
van Buuren, HR ;
van Hoogstraten, HJF ;
Terkivatan, T ;
Schalm, SW ;
Vleggaar, FP .
JOURNAL OF HEPATOLOGY, 2000, 33 (04) :543-548